Primary penile lymphoma is rarely observed in cases of extranodal malignant lymphoma. Owing principally to its rarity, no definite treatment modality has been established. We report the case of a 42-year-old man who presented with hematuria and a painless palpable mass on the penis which had persisted for 2 months. A 1.5 × 1.4 cm round mass was detected in the shaft of the penis. Histopathological examination of the excisional biopsy revealed CD20+ diffuse large B cell lymphoma. The patient was classified as having a stage IAE lymphoma. Because radiation often causes considerable early morbidity and later loss of function of the penis, 6 cycles of combination chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisolone) with rituximab were administered at 3-week intervals. After treatment, the patient showed a complete response and has maintained this status for the past 7 months. Multiple options, such as surgical amputation, radiotherapy and chemotherapy, are available for treatment of this condition. However, in order to minimize treatment-related morbidity and to maintain quality of life after treatment, combination chemotherapy including rituximab could be considered the treatment of choice after local excision.

Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.